Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.
about
Redefining the viral reservoirs that prevent HIV-1 eradicationTranscriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a curePersistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV modelImmune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence researchResidual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolutionA New Method for Rapid Screening of End-Point PCR Products: Application to Single Genome Amplified HIV and SIV Envelope AmpliconsResidual Viremia in Treated HIV+ IndividualsReview: Influence of ART on HIV geneticsThe detection and management of early HIV infection: a clinical and public health emergency.A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host.Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the TFH Cell Reservoir and Proposing Strategies to Overcome the Follicle SanctuaryAssociation between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adultsExpansion of dysfunctional Tim-3-expressing effector memory CD8+ T cells during simian immunodeficiency virus infection in rhesus macaquesPersistent production of an integrase-deleted HIV-1 variant with no resistance mutation and wild-type proviral DNA in a treated patientThe effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine modelAntiretroviral therapy: when to startEradicating HIV-1 infection: seeking to clear a persistent pathogen.Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict Clonality.Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.An increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cellsCell-associated HIV RNA: a dynamic biomarker of viral persistence.Modelling HIV-1 2-LTR dynamics following raltegravir intensification.HIV-1 transcription and latency: an update.Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, SpainPaired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.HIV-1 Latency and Eradication: Past, Present and FutureSpatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.Recent trends in HIV-1 drug resistance.From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.An integrated overview of HIV-1 latency.Understanding HIV compartments and reservoirs.Changes in HIV reservoirs during long-term antiretroviral therapy.Potential implication of residual viremia in patients on effective antiretroviral therapy.The Genotyping Resistance Profile of the Pol Gene Detected in Blood of Newly Diagnosed HIV-Positive Men Is Durably Archived in the Gut Whatever the Time of Initiation of cART.HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapyHIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy.Combination antiretroviral therapy and cell-cell spread of wild-type and drug-resistant human immunodeficiency virus-1.Persistent HIV-1 replication during antiretroviral therapy.Mechanisms of HIV persistence in HIV reservoirs.
P2860
Q26827255-CC460C7B-D6CC-41E8-AEE6-90A5F50FD0EBQ26999858-0EEE68BA-0A21-4D71-AA50-FB2CCB148224Q27335485-C48EC10E-22E5-4176-A332-6BBC27D6A388Q27687272-7B313641-E392-4609-A229-FA5A931DC890Q28077662-D24FAD05-C2FE-47C8-B284-FDDAF9FE758BQ28539563-F879FF7C-B56D-42F3-95CB-D0AFE44D364CQ28548014-732555E9-BD7D-4E5C-AB1B-717C3E4AD21CQ28552126-56B91C06-5A5B-4222-997A-A9E941969FFBQ28649848-8F5B1483-99C4-4325-9780-4DC9259D16BAQ33586581-C02B2902-4CCE-440B-AB91-94A8C8EE81C9Q33728690-48D7BB3E-CC92-4E19-9F26-98CD79B1EA49Q33742139-50E86E23-539C-40B4-9D53-F158E71397E7Q34057868-E1D525D7-4708-4FAD-9CC4-494DF30A9AE4Q34550643-77B4FD30-0037-4C49-8A5D-9A1FB68C80DDQ34871994-2C201406-1803-466F-95CD-76F6BD35C4FDQ35013818-9A2B60B1-43ED-4B8E-84BC-062166E11FD4Q35204279-B11791DB-A019-4CC5-90A5-78D811B25B52Q35252186-D1F3139F-E8F3-45C4-8F7B-A99E3A4645F4Q36095984-E51658B9-4C55-437C-A408-B21B0A155B51Q36172455-418AE92F-49B3-45CD-AC16-2C2DBA3A2E08Q36559821-39B0D2C4-78DD-4DA1-9EBF-D36C4E740FD4Q36798408-F022C1CA-4F6A-431D-8946-6AFDEC25D3DAQ36904249-2E9FD8F6-1CCB-4622-8C9E-2E63948E7B9CQ36976156-96A758E7-418F-4DFA-8073-C68CF93D7448Q37098390-447DA939-0053-4945-B71E-7F28DEF20849Q37493334-CBCC237D-AD01-4E34-AB2D-553AEB6D60A5Q37505823-981A7242-68F2-4618-BD87-9CAE5335A18CQ37621893-0D35D68C-1613-4C32-8C95-C27B033A067AQ37657560-CA4AFA14-527D-4DB4-B9F7-59FBC3876283Q38101294-06123DF3-0A3B-4549-96E8-78D0F96312F8Q38163449-88BA502D-A87F-42AD-928D-D8E7830E69C3Q38204313-A9457204-8D98-43BB-A430-74469738BC74Q38268762-BA4054C7-FE45-4CF8-B545-B89E5AD8F963Q38271917-01D0E15A-0091-4E0E-AD62-ED2AB4662C3CQ38375046-193CB519-5411-41C7-A225-7F1D03BD61DBQ38376002-F341FA30-65D6-485F-9D08-6C5639043C7DQ38380240-F04076AE-3A07-4281-B78D-2D939AF50F10Q38718627-456F2DE0-17EA-4A39-AF71-7DD3112F772AQ38808266-5465A288-9091-41C4-BC83-84B6DB8D1FA4Q39106572-15114D79-709C-469F-B111-0504024CF593
P2860
Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Absence of HIV-1 evolution in ...... ated during primary infection.
@ast
Absence of HIV-1 evolution in ...... ated during primary infection.
@en
type
label
Absence of HIV-1 evolution in ...... ated during primary infection.
@ast
Absence of HIV-1 evolution in ...... ated during primary infection.
@en
prefLabel
Absence of HIV-1 evolution in ...... ated during primary infection.
@ast
Absence of HIV-1 evolution in ...... ated during primary infection.
@en
P2093
P2860
P1433
P1476
Absence of HIV-1 evolution in ...... iated during primary infection
@en
P2093
Amir Figueroa
Hiroshi Mohri
Klara Tenner-Racz
Martin Markowitz
Saurabh Mehandru
Teresa H Evering
P2860
P304
P356
10.1371/JOURNAL.PPAT.1002506
P577
2012-02-02T00:00:00Z